Skip to Main Content

Paper Details

Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas.
Clin Cancer Res
14
2021
CAL27-TR, CRISPR, Erk1/2, HNSCC, HNSCC cell lines, HNSCCs, HSC3, HSC3-TR, Head and Neck Squamous Cell Carcinomas, Hippo, Hippo pathway, MEK, PDX, PDXs, Patient, RNA, Trametinib, Yap1, head and neck squamous cell carcinoma, parental HSC3, patient, patients, trametinib, tumor, tumors, verteporfin
Author NameAffiliation
Katie M CampbellMcDonnell Genome Institute and Department of Genetics, Washington University School of Medicine
Zachary L SkidmoreMcDonnell Genome Institute and Department of Genetics, Washington University School of Medicine
Erica K BarnellMcDonnell Genome Institute and Department of Genetics, Washington University School of Medicine
Gavin P DunnAlvin J. Siteman Cancer Center, Washington University School of Medicine
Gavin P DunnWashington University School of Medicine
Malachi GriffithMcDonnell Genome Institute and Department of Genetics, Washington University School of Medicine
Malachi GriffithAlvin J. Siteman Cancer Center, Washington University School of Medicine
Malachi GriffithWashington University School of Medicine
Ann Marie EgloffBrigham and Women's Hospital
Ann Marie EgloffBrigham and Women's Hospital
Obi L GriffithMcDonnell Genome Institute and Department of Genetics, Washington University School of Medicine
Obi L GriffithAlvin J. Siteman Cancer Center, Washington University School of Medicine
Obi L GriffithWashington University School of Medicine
Ravindra UppaluriDana-Farber Cancer Institute
Ravindra UppaluriBrigham and Women's Hospital
  • 1 - 15

Datasets

Release 1.2